ARTICLE | Clinical News
Tarceva erlotinib regulatory update
October 4, 2004 7:00 AM UTC
FDA accepted for filing an NDA for Tarceva as monotherapy to treat advanced non-small cell lung cancer (NSCLC) in patients who have failed chemotherapy. The small molecule inhibitor of epidermal grow...